This study reports the prognostic impact of the expression of the natural killer cell marker CD56 in a large series of risk-adapted paediatric patients with T cell acute lymphoblastic leukaemia (T-ALL; n = 493) treated within the ALL-Berlin-Frankfurt-M€ unster (BFM) 2000 protocol. The immunophenotype was analysed centrally at diagnosis using flow cytometry and correlated with clinical parameters and outcome. CD56 expression was detected in 7Á1% and early T-cell precursor (ETP) phenotype in 6Á7% of all T-ALL patients. The percentage of ETP in the CD56+ T-ALL cohort was 4-fold higher than in the whole cohort. CD56+ T-ALL frequently expressed the progenitor marker CD34 and myeloid antigens CD13 and CD33. The 5-year event-free survival (EFS) rates for the European Group for the Immunological classification of Leukaemias/World Health Organization subgroups and the ETP phenotype were not statistically different. By contrast, patients with CD56 expression had a significantly reduced EFS (60 AE 8%) and overall survival (60 AE 8%) at 5 years, with a hazard ratio of 2Á46 (P = 0Á002) and 2Á99 (P < 0Á001), respectively. Moreover, CD56 expression in combination with the minimal residual disease (MRD)-based high risk assignment defined a population with a 'very-high' risk probability of relapse in the ALL-BFM 2000 trial. The CD56 marker has the potential to augment MRD-based risk stratification and may serve as a molecular target for antibody-based treatment strategies in childhood T-ALL.
Summary
This study reports the prognostic impact of the expression of the natural killer cell marker CD56 in a large series of risk-adapted paediatric patients with T cell acute lymphoblastic leukaemia (T-ALL; n = 493) treated within the ALL-Berlin-Frankfurt-M€ unster (BFM) 2000 protocol. The immunophenotype was analysed centrally at diagnosis using flow cytometry and correlated with clinical parameters and outcome. CD56 expression was detected in 7Á1% and early T-cell precursor (ETP) phenotype in 6Á7% of all T-ALL patients. The percentage of ETP in the CD56+ T-ALL cohort was 4-fold higher than in the whole cohort. CD56+ T-ALL frequently expressed the progenitor marker CD34 and myeloid antigens CD13 and CD33. The 5-year event-free survival (EFS) rates for the European Group for the Immunological classification of Leukaemias/World Health Organization subgroups and the ETP phenotype were not statistically different. By contrast, patients with CD56 expression had a significantly reduced EFS (60 AE 8%) and overall survival (60 AE 8%) at 5 years, with a hazard ratio of 2Á46 (P = 0Á002) and 2Á99 (P < 0Á001), respectively. Moreover, CD56 expression in combination with the minimal residual disease (MRD)-based high risk assignment defined a population with a 'very-high' risk probability of relapse in the ALL-BFM 2000 trial. The CD56 marker has the potential to augment MRD-based risk stratification and may serve as a molecular target for antibody-based treatment strategies in childhood T-ALL.
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Expression of CD56 (neural cell adhesion molecule), a member of the immunoglobulin family of adhesion molecules is the prototypic marker of natural killer (NK) cells (CD3ÀCD56+) and NK-like T lymphocytes (CD3+CD56+) in normal haematopoiesis. NK cells primarily develop in the bone marrow (BM) from ancestors of haematopoetic stem cells. The classical theory postulated an early commitment of multipotent progenitors (MPPs) towards the lymphoid or myeloid lineage after they left the BM. This model has been challenged by the identification of lymphoid-primed MPP with lymphoid and myeloid potential that can populate the thymus (Koch & Radtke, 2011) . The identity of these thymus-seeding progenitors is a subject of debate but clearly involves cells with a developmental potential for T/NK as well as other non-T cell lineages (Klein Wolterink et al, 2010) .
Although pure NK cell neoplasms are rare, CD56 expression can be aberrantly found on different haematological malignancies, such as myeloma (Harada et al, 1993) , acute myeloid leukaemia (AML) (Seymour et al, 1994) and lymphoblastic leukaemia (ALL) (Paietta et al, 2001) . Apart from being useful in identifying a malignant cell clone, it is also of prognostic relevance in certain haematological malignancies (Baer et al, 1997; Raspadori et al, 2001) . In particular in a subgroup of acute myeloid leukaemia, the acute promyelocytic leukemia, CD56 expression has been associated with an inferior clinical outcome (Montesinos et al, 2011) .
In adult T cell acute lymphoblastic leukaemia (T-ALL), CD56-positive cases revealed higher resistance to initial therapy but no inferior survival after risk-adapted therapy (Fischer et al, 2009 ). Paediatric T-ALLs have only been reported so far either in a very small series of patients (Montero et al, 2003) , or in a mixed cohort of paediatric/ adult T-ALLs (Dalmazzo et al, 2009 ). Here we report the expression and prognostic impact of CD56 in a large series of paediatric T-ALL patients (n = 493) treated within the multicentre ALL-Berlin-Frankfurt-M€ unster (BFM) 2000 study (Schrappe et al, 2011) .
Patients and methods

Study population
Patients with T-ALL were enrolled in the BFM multicentre trial ALL-BFM 2000 for the treatment of childhood ALL (age: 1-18 years) (ClinicalTrials.gov Identifier: NCT00 430118). Details of the treatment protocol have been published previously (Schrappe et al, 2011) . The competent ethics committees of the Hannover Medical School, Hannover, approved the study protocol. The patients or legal guardians gave informed consent in accordance with the Helsinki protocol. Between August 1999 and May 2010 4035 patients were recruited at the participating centres in Germany; 574 were diagnosed with T-ALL. All of the 493 patients (86%) with central flow cytometry immunophenotyping were included in this study. There were no significant differences between patients with and without immunophenotyping data regarding sex distribution (P = 0Á14) and response parameters (prednisone response P = 0Á77; minimal residual disease [MRD] risk group P = 0Á33; remission at Day 33 P = 0Á16). The diagnosis of T-ALL was based on morphology and immunophenotype. The subclassification of T-ALL into T1 (pro-T-ALL), T2 (pre-T-ALL), T3 (cortical T-ALL), T4 (mature T-ALL) subgroups was performed using criteria adopted from the guidelines proposed by the European Group for the Immunological classification of Leukaemias (EGIL) (Bene et al, 1995) . The early T-cell precursor (ETP) subtype was identified according to the immunophenotypic definition of Coustan-Smith et al (2009) (see section on immunophenotyping for details).
Immunophenotyping
Mononuclear cells were isolated with Ficoll gradient centrifugation, washed and stained with combinations of fluorochrome-conjugated monoclonal antibody panel composed of 11 tubes each containing four-color antibody combinations (Table SI) (Ratei et al, 2013) . Samples were acquired on a FACS Calibur (BD Biosciences, Heidelberg, Germany).
Quality control with beads for laser performance and compensation was performed weekly. Antigen-negative subpopulations of cells in each tube were used as negative controls. The blast population was gated using scatter parameters and antigen expression was rated positive when >20% of blasts reacted with the monoclonal antibodies according to the EGIL criteria (Bene et al, 1995) , as described previously (Ratei et al, 2013) . According to Coustan-Smith et al (2009) the ETP ALL phenotype was defined by: lack of CD1a and CD8 expression, weak CD5 expression with less than 75% positive blasts, and expression of one or more of the following myeloid or stem cell markers: CD117, CD34, HLA-DR, CD13, CD33, and/or CD65 according to EGIL (Bene et al, 1995) . CD11b was not measured.
Analysis of genetic data
Conventional cytogenetic analysis was not mandatory in the protocol and was therefore not systematically obtained. Samples with sufficient DNA available were analysed for mutations in NOTCH1 (PEST-domain, TAD-domain, N-terminal and C-terminal heterodimerization domain) (Breit et al, 2006) , PTEN (exon 7) (Bandapalli et al, 2013) and FBXW7 (exons 9 and 10) (Kox et al, 2010) by Sanger-sequencing after polymerase chain reaction (PCR) amplification. Copy number alterations were analysed by multiplex ligationdependent probe amplification (MLPA) using the commercially available SALSA MLPA P383 T-ALL probe mix (MRC-Holland, Amsterdam, The Netherlands).
Statistical analysis
All patient data were updated in January 2017. Event-free survival (EFS) and overall survival (OS) were defined as published previously (Moricke et al, 2016) . Statistical analyses, including the Kaplan-Meier method, Cox proportional hazards and Fine and Gray model for multivariate analysis, cumulative incidence functions for competing events, the chi-squared test and the Mann-Whitney U, were conducted using SPSS version 21.0 (IBM, Ehningen, Germany) and SAS (SAS-PC, version 9.4; SAS Institute, Cary, NC). A P value <0Á05 was considered to be statistically significant.
Results
Of 493 T-ALL patients, 487 (98Á8%) could be classified according to the EGIL classification (Bene et al, 1995) . Six patients could be classified as T-ALL but no subtype according to EGIL could be assigned. The frequency of the T1-T4 subgroups were: T3: 64Á9%, T2: 19Á3%, T4: 14Á8% and T1: 1%. Thirty-three patients (6Á7%) were classified as ETP-ALL and were considered as a separate subgroup in the following analyses. Thirty-five (7Á1%) patients were positive for CD56. The frequency of CD56-positive cases differed between the T-ALL subgroups (Table I) (Table I) .
The available information on conventional cytogenetics is summarized in Table SII) . Although data on conventional cytogenetics were limited, the mutational status was available for 22 of 35 CD56-positive patients (63%), with mutations in NOTCH1, PTEN and FBXW7 in 10/22, 1/22 patients and 2/22 patients, respectively. The proportions of patients carrying these mutations were not significantly different from the total ALL-BFM 2000 cohort (Breit et al, 2006; Kox et al, 2010; Bandapalli et al, 2013) .
With regard to the demographic and baseline characteristics for CD56-positive patients, the majority of the parameters were not significantly different compared to the CD56-negative cohort (Table II) . However, the CD56-positive cases CD56-positive, N (%) CD56-negative, N (%) P (Fishers exact 2-sided) revealed a significantly lower (by almost a 3-fold difference) leucocyte count as well as a higher probability for the absence of molecular markers for PCR detection of MRD (20% vs. 12%).
We further addressed clinical impact in CD56-positive and ETP T-ALL subgroups (Table II) . With regard to induction therapy response parameters, CD56-positive T-ALLs were more likely to fail a cytological remission and had higher MRD levels. This was also reflected in the significantly more frequent assignment to the MRD-PCR high risk (HR) group. In accordance with numerous clinical trials, we did not observe statistically significant differences between T1, T2, T3 and T4 subtypes (Brammer et al, 2017; Fukano et al, 2018) (Fig 1A, B) . We also did not observe prognostic significance of the ETP-phenotype. In contrast, CD56-positive patients had a significantly inferior 5-year EFS (60 AE 8% vs. 82 AE 2%, P = 0Á002; hazard ratio 2Á3, CI 1Á4-4Á0), and these patients also had a markedly reduced overall survival (60 AE 8% vs. 85 AE 2%, P = 0Á003; hazard ratio 2Á7, CI 1Á5-4Á8). These differences remained with longer follow-up (Fig 1C, D) . The difference in the EFS was mainly caused by the higher incidence of relapse in CD56-positive patients (29 AE 8% vs. 12 AE 2%, P = 0Á003; hazard ratio 2Á4, CI 1Á2-4Á7). CD56-positive patients had the worse outcome irrespective of the presence or absence of the activating NOTCH1 mutations (Fig 2) . In order to differentiate overlapping cases we evaluated the outcomes for the ETP/CD56 subgroups. With the limitation of small patient numbers within the groups, this analysis shows a trend towards inferior outcome for the CD56-positive cases (P = 0Á08 for CD56+/ETPÀ vs. CD56À/ETP+).
Given considerable differences in the post-induction therapy between the PCR-MRD intermediate risk (IR)-and HRgroups, we analysed the predictive impact of CD56 in these subgroups separately. EFS was slightly lower, but not significantly different in MRD-IR patients (P = 0Á23). Most importantly, in the HR CD56-positive patients had an inferior EFS (P = 0Á019; Fig 3D) . The hazard ratio for CD56 was similar in the IR (1Á92, CI 0Á7-5Á4) and HR (2Á1, CI 1Á1-4Á0) groups.
A multivariate analysis was performed to explore the prognostic impact of CD56 expression on EFS in conjunction with the immunophenotype and very early clinical riskrelated factors (CD13, CD33, CD34, ETP, age ≥10 years, white blood cell count ≥100 9 10 9 /l and prednisone response). CD56 expression and prednisone response were statistically significant independent risk parameters in this scenario. With the addition of MRD status (Schrappe et al, 2011) to the risk factors, CD56 lost its independent prognostic significance in the whole cohort (i.e. composed of IR and HR patients) (Table SIII) .
Discussion
This study analyses immunophenotypic characteristics in the largest cohort of T-ALL paediatric patients treated with a standardized, risk-adapted therapy protocol. The study also benefits from the long follow-up period for the clinical outcome of these patients. The distribution of phenotypes according to EGIL was comparable to the previous ALL-BFM (Moricke et al, 2010; Ratei et al, 2013) and other international trials (Pui et al, 2011 The CD56-positive cases were characterized by a more frequent expression of myeloid and progenitor markers. In accordance with observations for adult CD56-positive T-ALL (Fischer et al, 2009) , these findings support the notion of a common T/NK/myeloid precursor cell as the biological origin of CD56-positive T-ALLs. The frequency of mutations in NOTCH1, PTEN and FBXW7 in these patients did not differ significantly from the total cohort, meaning that we could not link the specific immunophenotype with one of the established mutations in T-ALL (Girardi et al, 2017) .
The most important clinical observation in this study is the significant inferior EFS and OS of CD56-positive patients that persisted throughout the follow-up of nearly 10 years. Our analysis also expands findings of a previous study on the relevance of the MRD status in this cohort (Schrappe et al, 2011) as we could retrospectively identify CD56-expression as an important modifying factor for outcome prediction. CD56 expression was an additional unfavourable factor for risk of relapse within the MRD-high risk group, although these patients received an intensified, MRD tailored treatment within the protocol to improve the inferior outcome. Notably, the majority of relapses in this very-high risk group occurred in the first 18 months after diagnosis (Fig 3B) , the time-to-relapse parameter considered to be an adverse risk factor in relapsed ALL (Henze et al, 2013) . We did not observe a detrimental effect of the ETP phenotype on EFS and OS, thereby confirming results published by the AIEOP and other (Patrick et al, 2014; Wood et al, 2014) groups, which suggested that current protocols are able to overcome the potentially negative prognostic impact of the ETP phenotype. Our data also suggest, though with the limitation of the small number of cases, that CD56 expression could possibly be a prognostic factor within the ETP subgroup.
In summary, this analysis of the ALL-BFM 2000 trial indicates that CD56-positive T-ALL is a distinct subgroup of T-ALL, with putative T-NK-cell precursor (T-NKP) origin, comprising about 7% of all paediatric patients, and characterised by a lower leucocyte count at presentation, more frequent expression of progenitor (CD34) and myeloid antigens (CD13 and CD33) at diagnosis. Clinically, CD56-positive cases were less sensitive to the remission induction and consolidation part of the protocol (Moricke et al, 2016) , thus indicating that CD56 expression in T-ALL has a potential as an important prognostic marker already available at diagnosis, a finding that should be validated prospectively in an independent cohort. Importantly, in spite of the frequent assignment to the MRD-HR group, the risk-adapted therapy was still less effective within this group, resulting in the significantly lower EFS and OS. This indicates the necessity of alternative therapeutic options to the conventional treatment intensification. To this end, the high levels of the CD56 surface expression would provide an attractive molecular target for antibody-based treatment strategies in childhood T-ALL.
2 CD56 expression in combination with the MRD-based high risk assignment defines a population with a 'veryhigh' risk probability of relapse.
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